Our data revealed a previously unidentified functional and mechanistic link between EZH2 levels, CHK1 signaling activation, and ovarian CSCs and provided strong evidence that EZH2 promotes ovarian cancer chemoresistance and recurrence.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: